The Guardian Australia
·general
·1 hour ago
Oral pill orforglipron helps patients keep most weight loss after stopping GLP1
A daily pill called orforglipron helped patients maintain most weight loss after stopping injectable GLP1 drugs in a trial of 376 U.S. participants. Those switching from tirzepatide kept 75% of weight lost versus 49% on placebo; semaglutide switchers retained 80% versus 38% on placebo. The cheaper oral option could reduce reliance on multiple medications for obesity-related diseases.
Summary by Glance · The Guardian Australia
Newer
Next
Loving doing this? 🎉
Take it further — get the full app and never miss a moment of what's happening in Australia.
Breaking news alerts
Instant lock-screen notifications the moment big stories break across Australia.
Australian news & events
Politics, sport, weather, local events — all in one swipeable feed, updated around the clock.
Stay ahead of the news cycle
30-second summaries so you're always informed, even on your busiest days.
Loading article…
This publisher's site can't be shown here due to their security settings.
Open full article →No source link available for this article.
✨
Ask AI